Login
Companies $LCTX
$0.80 +$0.00 (0.0%) After hours
Lineage Cell Therapeutics, Inc. logo

Lineage Cell Therapeutics, Inc.

lineagecell.com

What Do They Do?

Develops cell replacement therapies for patients with serious conditions, including retinal disease, spinal cord injury and hearing loss.

How Do They Make Money?

Lineage gets upfront license fees and milestone payments from collaborators, and is paid for research work as it progresses. It also earns royalties and service revenue under royalty and service agreements.

revenue
SegmentShareRevenue
Collaboration Revenues
Mix

93%
FY2022: 91%
Royalties, License and Other Revenues
Licensed
6.5%
FY2022: 9.1%

Who Are Their Customers?

Partners collaborate directly with Lineage on cell-development programs, including Roche for OpRegen and WDI for ReSonance.

Do Revenues Turn Into Profits?

No. It lost $63.5M in FY2025.

Operating income, FY2025
−252% of revenue
▼ −70% (Loss) vs FY2024 (−$21.5M, −226%)
Net income, FY2025
−436% of revenue
▼ −241% (Loss) vs FY2024 (−$18.6M, −196%)
Free cash flow, FY2025
−134% of revenue
▲ +18% (Loss) vs FY2024 (−$23.7M, −249%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −61%
vs $3.7M in Q3 FY2025
Net income
▲ Turned profitable
vs −$29.8M in Q3 FY2025
Collaboration Revenues share of revenue vs 96.3% in Q3 FY2025
  • Nov 12, 2026 Acquired NeuroAirmid, adding the HUNT1 cell therapy program NeuroAirmid became a wholly owned subsidiary, bringing in a clinical-stage program for Huntington’s disease.

Growing. Revenue grew 3.4x in 4 years, from $4.3M in FY2021 to $14.6M in FY2025, about 35% a year.

Pipeline focus The older report included a dendritic-cell cancer immunotherapy program; the latest overview instead describes cell replacement programs for retinal disease, spinal cord injury and hearing loss.

Revenue over time
Collaboration Revenues Royalties, License and Other Revenues Royalties Grant Revenues
$20M$10M$0

Who Do They Compete With?

Competes with Abbvie, Century Therapeutics, Bayer, Regeneron Pharmaceuticals, Santen Pharmaceuticals, Sana Biotechnology, jCyte, Astellas Pharma, and Apellis Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support